Neuroprotective role of natural polyphenols

Current Topics in Medicinal Chemistry

Volumn 16, Issue 17, 2016, Pages 1943-1950

  Spagnuolo, Carmela ^a   Napolitano, Marianna ^a   Tedesco, Idolo ^a   Moccia, Stefania ^a   Milito, Alfonsina ^a   Russo, Gian Luigi ^a  

^a CNR   (Italy)

Author keywords

Alzheimer Disease; Elderberry; Neurodegeneration; Polyphenols; Sambucus nigra

Indexed keywords

ANTHOCYANIN; BROXURIDINE; CASPASE; COUMARIC ACID; CURCUMIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLOOXYGENASE 2; FLAVONOID; GALLIC ACID; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 16; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHENOL DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOALEXIN; PLANT EXTRACT; POLYPHENOL DERIVATIVE; PROANTHOCYANIDIN DERIVATIVE; PROTEIN KINASE B; QUERCETIN; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; SAMBUCUS NIGRA EXTRACT; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL PRODUCT; NEUROPROTECTIVE AGENT; POLYPHENOL;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CHELATION; COGNITION; DEGENERATIVE DISEASE; DEMENTIA; ENZYME ACTIVITY; GRAPE JUICE; HUMAN; HYDROXYLATION; LEARNING; LIPID PEROXIDATION; MEMORY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; ANIMAL; CHEMISTRY; NEURODEGENERATIVE DISEASES;

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; POLYPHENOLS;

EID: 84974691240     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160204122449     Document Type: Article

References (84)

1. Hoglund, K.; Salter, H. Molecular biomarkers of neurodegeneration. Expert Rev. Mol. Diagn., 2013, 13(8), 845-861.
2. McKhann, G. M.; Knopman, D. S.; Chertkow, H.; Hyman, B. T.; Jack, C. R., Jr.; Kawas, C. H.; Klunk, W. E.; Koroshetz, W. J.; Manly, J. J.; Mayeux, R.; Mohs, R. C.; Morris, J. C.; Rossor, M. N.; Scheltens, P.; Carrillo, M. C.; Thies, B.; Weintraub, S.; Phelps, C. H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7(3), 263-269.
3. Ford, A. H. Neuropsychiatric aspects of dementia. Maturitas, 2014, 79(2), 209-215.
4. Mielke, M. M.; Vemuri, P.; Rocca, W. A. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin. Epidemiol., 2014, 6, 37-48.
5. Reitz, C.; Mayeux, R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol., 2014, 88(4), 640-651.
6. Casetta, I.; Govoni, V.; Granieri, E. Oxidative stress, antioxidants and neurodegenerative diseases. Curr. Pharm. Des., 2005, 11(16), 2033-2052.
7. Spires-Jones, T. L.; Hyman, B. T. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron, 2014, 82(4), 756-771.
8. Sorrentino, P.; Iuliano, A.; Polverino, A.; Jacini, F.; Sorrentino, G. The dark sides of amyloid in Alzheimer's disease pathogenesis. FEBS Lett., 2014, 588(5), 641-652.
9. Pooler, A. M.; Noble, W.; Hanger, D. P. A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology, 2014, 76(Pt A), 1-8.
10. Goedert, M.; Clavaguera, F.; Tolnay, M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci., 2010, 33(7), 317-325
11. Ferrer, I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog. Neurobiol., 2012, 97(1), 38-51.
12. Han, S. H.; Mook-Jung, I. Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease. J. Korean. Med. Sci., 2014, 29(7), 893-902.
13. Gonzalez, H.; Elgueta, D.; Montoya, A.; Pacheco, R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J. Neuroimmunol., 2014, 274(1-2), 1-13.
14. Suzumura, A. Neuron-microglia interaction in neuroinflammation. Curr. Protein Pept. Sci., 2013, 14(1), 16-20.
15. Russo, G. L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol., 2007, 74(4), 533-544
16. Russo, M.; Spagnuolo, C.; Tedesco, I.; Russo, G. L. Phytochemicals in cancer prevention and therapy: truth or dare? Toxins (Basel), 2010, 2(4), 517-551.
17. Leopoldini, M. R., N. Toscano, M. The molecular basis of working mchanism of natural polyphenolic antioxidants. Food Chem., 2011, 125, 288-306.
18. Senanayake, N. S. P. J. Green tea extract: Chemistry, antioxidant properties and food applications-A review. J. Funct. Foods, 2013, 5, 1529-1541
19. Vattem, D. S., K Biological functionality of ellagic acid: a review. J. Food Biochem., 2005, 29, 234-266
20. Smid, S. D.; Maag, J. L.; Musgrave, I. F. Dietary polyphenol-derived protection against neurotoxic beta-amyloid protein: from molecular to clinical. Food Funct., 2012, 3(12), 1242-1250
21. Visioli, F.; Bellomo, G.; Galli, C. Free radicalscavenging properties of olive oil polyphenols. Biochem. Biophys. Res. Commun., 1998, 247(1), 60-64
22. Nabavi, S. M.; Nabavi, S. F.; Eslami, S.; Moghaddam, A. H. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food Chem., 2012 132, 931-935.
23. Kang, N. J.; Shin, S. H.; Lee, H. J.; Lee, K. W. Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol. Ther., 2011, 130(3), 310-324.
24. Russo, G. L.; Russo, M.; Spagnuolo, C. The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia. Food Funct., 2014, 5(10), 2393-2401
25. Russo, G. L.; Russo, M.; Spagnuolo, C.; Tedesco, I.; Bilotto, S.; Iannitti, R.; Palumbo, R. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat. Res., 2014, 159, 185-205.
26. Yang, S.; Irani, K.; Heffron, S. E.; Jurnak, F.; Meyskens, F. L., Jr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther., 2005, 4(12), 1923-1935.
27. Zykova, T. A.; Zhu, F.; Zhai, X.; Ma, W. Y.; Ermakova, S. P.; Lee, K. W.; Bode, A. M.; Dong, Z. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol. Carcinog., 2008, 47(10), 797-805.
28. Han, S. S.; Keum, Y. S.; Seo, H. J.; Surh, Y. J. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol., 2002, 35(3), 337-342.
29. Balasubramanyam, K.; Varier, R. A.; Altaf, M.; Swaminathan, V.; Siddappa, N. B.; Ranga, U.; Kundu, T. K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem., 2004, 279(49), 51163-51171.
30. Erlund, I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr. Res., 2004, 24, 851-874.
31. Daglia, M. Polyphenols as antimicrobial agents. Curr. Opin. Biotechnol., 2012, 23, 174-181.
32. Nabavi, S. F.; Daglia, M.; Moghaddam, A. H.; Habtemariam, S.; Nabavi, S. M. Curcumin and Liver Disease: from Chemistry to Medicine. Compr. Rev. Food Sci. Food Saf., 2014, 13(1), 62-77.
33. Gu, Y.; Nieves, J. W.; Stern, Y.; Luchsinger, J. A.; Scarmeas, N. Food combination and Alzheimer disease risk: a protective diet. Arch. Neurol., 2010, 67(6), 699-706
34. Barberger-Gateau, P.; Raffaitin, C.; Letenneur, L.; Berr, C.; Tzourio, C.; Dartigues, J. F.; Alperovitch, A. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology, 2007, 69(20), 1921-1930.
35. Lindsay, J.; Laurin, D.; Verreault, R.; Hebert, R.; Helliwell, B.; Hill, G. B.; McDowell, I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol., 2002, 156(5), 445-453.
36. Mandel, S. A.; Amit, T.; Weinreb, O.; Youdim, M. B. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J. Alzheimers Dis., 2011, 25(2), 187-208.
37. Dai, Q.; Borenstein, A. R.; Wu, Y.; Jackson, J. C.; Larson, E. B. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am. J. Med., 2006, 119(9), 751-759.
38. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res., 2004, 75(6), 742-750
39. Vingtdeux, V.; Giliberto, L.; Zhao, H.; Chandakkar, P.; Wu, Q.; Simon, J. E.; Janle, E. M.; Lobo, J.; Ferruzzi, M. G.; Davies, P.; Marambaud, P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem., 2010, 285(12), 9100-9113
40. Jimenez-Aliaga, K.; Bermejo-Bescos, P.; Benedi, J.; Martin-Aragon, S. Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci., 2011, 89(25-26), 939-945.
41. Riviere, C.; Richard, T.; Quentin, L.; Krisa, S.; Merillon, J. M.; Monti, J. P. Inhibitory activity of stilbenes on Alzheimer's betaamyloid fibrils in vitro. Bioorg. Med. Chem., 2007, 15(2), 1160-1167
42. Ladiwala, A. R.; Lin, J. C.; Bale, S. S.; Marcelino-Cruz, A. M.; Bhattacharya, M.; Dordick, J. S.; Tessier, P. M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J. Biol. Chem., 2010, 285(31), 24228-24237.
43. Ehrnhoefer, D. E.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; Engemann, S.; Pastore, A.; Wanker, E. E. EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat. Struct. Mol. Biol., 2008, 15(6), 558-566.
44. Miyata, M.; Sato, T.; Kugimiya, M.; Sho, M.; Nakamura, T.; Ikemizu, S.; Chirifu, M.; Mizuguchi, M.; Nabeshima, Y.; Suwa, Y.; Morioka, H.; Arimori, T.; Suico, M. A.; Shuto, T.; Sako, Y.; Momohara, M.; Koga, T.; Morino-Koga, S.; Yamagata, Y.; Kai, H. The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry, 2010, 49(29), 6104-6114.
45. Hudson, S. A.; Ecroyd, H.; Dehle, F. C.; Musgrave, I. F.; Carver, J. A. (-)-Epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway. J. Mol. Biol., 2009, 392(3), 689-700.
46. Mandel, S.; Amit, T.; Bar-Am, O.; Youdim, M. B. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol., 2007, 82(6), 348-360.
47. Moreira, P. I.; Honda, K.; Liu, Q.; Santos, M. S.; Oliveira, C. R.; Aliev, G.; Nunomura, A.; Zhu, X.; Smith, M. A.; Perry, G. Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Curr. Alzheimer Res., 2005, 2(4), 403-408.
48. Scapagnini, G.; Vasto, S.; Abraham, N. G.; Caruso, C.; Zella, D.; Fabio, G. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol. Neurobiol., 2011, 44(2), 192-201
49. Sreejayan; Rao, M. N. Nitric oxide scavenging by curcuminoids. J. Pharm. Pharmacol., 1997, 49(1), 105-107
50. Ansari, M. A.; Abdul, H. M.; Joshi, G.; Opii, W. O.; Butterfield, D. A. Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. J. Nutr. Biochem., 2009, 20(4), 269-275
51. Biasibetti, R.; Tramontina, A. C.; Costa, A. P.; Dutra, M. F.; Quincozes-Santos, A.; Nardin, P.; Bernardi, C. L.; Wartchow, K. M.; Lunardi, P. S.; Goncalves, C. A. Green tea (-)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav. Brain Res., 2013, 236(1), 186-193.
52. Adams, B. K.; Cai, J.; Armstrong, J.; Herold, M.; Lu, Y. J.; Sun, A.; Snyder, J. P.; Liotta, D. C.; Jones, D. P.; Shoji, M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs, 2005, 16(3), 263-275
53. He, M.; Zhao, L.; Wei, M. J.; Yao, W. F.; Zhao, H. S.; Chen, F. J. Neuroprotective effects of (-)-epigallocatechin-3-gallate on aging mice induced by D-galactose. Biol. Pharm. Bull., 2009, 32(1), 55-60
54. Kumar, A.; Naidu, P. S.; Seghal, N.; Padi, S. S. Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology, 2007, 79(1), 17-26.
55. Spencer, J. P.; Vafeiadou, K.; Williams, R. J.; Vauzour, D. Neuroinflammation: modulation by flavonoids and mechanisms of action. Mol. Aspects Med., 2012, 33(1), 83-97.
56. Jayasena, T.; Poljak, A.; Smythe, G.; Braidy, N.; Munch, G.; Sachdev, P. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease. Ageing Res. Rev., 2013, 12(4), 867-883.
57. Ray, B.; Lahiri, D. K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr. Opin. Pharmacol., 2009, 9(4), 434-444.
58. Lee, Y. J.; Choi, D. Y.; Yun, Y. P.; Han, S. B.; Oh, K. W.; Hong, J. T. Epigallocatechin-3-gallate prevents systemic inflammationinduced memory deficiency and amyloidogenesis via its antineuroinflammatory properties. J. Nutr. Biochem., 2013, 24(1), 298-310.
59. Wight, R. D.; Tull, C. A.; Deel, M. W.; Stroope, B. L.; Eubanks, A. G.; Chavis, J. A.; Drew, P. D.; Hensley, L. L. Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases. Biochem. Biophys. Res. Commun., 2012, 426(1), 112-115
60. Capiralla, H.; Vingtdeux, V.; Zhao, H.; Sankowski, R.; Al-Abed, Y.; Davies, P.; Marambaud, P. Resveratrol mitigates lipopolysaccharide-and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade. J. Neurochem., 2012, 120(3), 461-472.
61. Joseph, J. A.; Shukitt-Hale, B.; Willis, L. M. Grape juice, berries, and walnuts affect brain aging and behavior. J. Nutr., 2009, 139(9), 1813S-1817S.
62. Cherniack, E. P. A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders. Br. J. Nutr., 2012, 108(5), 794-800.
63. Krikorian, R.; Nash, T. A.; Shidler, M. D.; Shukitt-Hale, B.; Joseph, J. A. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br. J. Nutr., 2010, 103(5), 730-734.
64. Remington, R.; Chan, A.; Lepore, A.; Kotlya, E.; Shea, T. B. Apple juice improved behavioral but not cognitive symptoms in moderate-to-late stage Alzheimer's disease in an open-label pilot study. Am. J. Alzheimers Dis. Other Demen., 2010, 25(4), 367-371.
65. Krikorian, R.; Shidler, M. D.; Nash, T. A.; Kalt, W.; Vinqvist-Tymchuk, M. R.; Shukitt-Hale, B.; Joseph, J. A. Blueberry supplementation improves memory in older adults. J. Agric. Food Chem., 2010, 58(7), 3996-4000.
66. Wang, J.; Bi, W.; Cheng, A.; Freire, D.; Vempati, P.; Zhao, W.; Gong, B.; Janle, E. M.; Chen, T. Y.; Ferruzzi, M. G.; Schmeidler, J.; Ho, L.; Pasinetti, G. M. Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Front. Aging Neurosci., 2014, 6(42), 1-10.
67. Tumilowicz, J. J.; Nichols, W. W.; Cholon, J. J.; Greene, A. E. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res., 1970, 30(8), 2110-2118.
68. Kume, T.; Kawato, Y.; Osakada, F.; Izumi, Y.; Katsuki, H.; Nakagawa, T.; Kaneko, S.; Niidome, T.; Takada-Takatori, Y.; Akaike, A. Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype. Neurosci. Lett., 2008, 443(3), 199-203.
69. Lehner, B.; Sandner, B.; Marschallinger, J.; Lehner, C.; Furtner, T.; Couillard-Despres, S.; Rivera, F. J.; Brockhoff, G.; Bauer, H. C.; Weidner, N.; Aigner, L. The dark side of BrdU in neural stem cell biology: detrimental effects on cell cycle, differentiation and survival. Cell Tissue Res., 2011, 345(3), 313-328.
70. Yankner, B. A.; Duffy, L. K.; Kirschner, D. A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 1990, 250(4978), 279-282.
71. Calissano, P.; Matrone, C.; Amadoro, G. Apoptosis and in vitro Alzheimer disease neuronal models. Commun. Integr. Biol., 2009, 2(2), 163-169.
72. Lewandowska, U.; Szewczyk, K.; Hrabec, E.; Janecka, A.; Gorlach, S. Overview of metabolism and bioavailability enhancement of polyphenols. J. Agric. Food Chem., 2013, 61(50), 12183-12199.
73. Bilotto, S. S., C Russo, MTedesco, I Laratta, B Russo, GL Dietary Phytochemicals in Chemoprevention of Cancer: An Update. Immun. Endoc. & Metab. Agents Med. Chem., 2013, 13, 2-24.
74. Abbott, N. J.; Romero, I. A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today, 1996, 2(3), 106-113.
75. Faria, A.; Pestana, D.; Teixeira, D.; Couraud, P. O.; Romero, I.; Weksler, B.; de Freitas, V.; Mateus, N.; Calhau, C. Insights into the putative catechin and epicatechin transport across blood-brain barrier. Food Funct., 2011, 2(1), 39-44
76. Faria, A.; Meireles, M.; Fernandes, I.; Santos-Buelga, C.; Gonzalez-Manzano, S.; Duenas, M.; de Freitas, V.; Mateus, N.; Calhau, C. Flavonoid metabolites transport across a human BBB model. Food Chem., 2014, 149, 190-196.
77. Abd El Mohsen, M. M.; Kuhnle, G.; Rechner, A. R.; Schroeter, H.; Rose, S.; Jenner, P.; Rice-Evans, C. A. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic. Biol. Med., 2002, 33(12), 1693-1702
78. Talavera, S.; Felgines, C.; Texier, O.; Besson, C.; Gil-Izquierdo, A.; Lamaison, J. L.; Remesy, C. Anthocyanin metabolism in rats and their distribution to digestive area, kidney, and brain. J. Agric. Food Chem., 2005, 53(10), 3902-3908
79. Youdim, K. A.; Shukitt-Hale, B.; Joseph, J. A. Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system. Free Radic. Biol. Med., 2004, 37(11), 1683-1693.
80. Mattson, M. P.; Cheng, A. Neurohormetic phytochemicals: Lowdose toxins that induce adaptive neuronal stress responses. Trends Neurosci., 2006, 29(11), 632-639.
81. Mattson, M. P.; Son, T. G.; Camandola, S. Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response, 2007, 5(3), 174-186.
82. Singleton, V. L.; Rossi Jr, J. A. Colorimetry of total phenolics with phoshomolybdic-phosphotungstic acid reagents. Am. J. Enol. Vitic., 1965, 16, 144-158.
83. Benzie, I. F.; Strain, J. J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal. Biochem., 1996, 239(1), 70-76.
84. Russo, M.; Spagnuolo, C.; Volpe, S.; Mupo, A.; Tedesco, I.; Russo, G. L. Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. Br. J. Cancer, 2010, 103(5), 642-648.